Invuity, Inc. (IVTY) Expected to Announce Earnings of -$0.55 Per Share
Brokerages expect Invuity, Inc. (NASDAQ:IVTY) to report ($0.55) earnings per share for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for Invuity’s earnings, with the highest EPS estimate coming in at ($0.48) and the lowest estimate coming in at ($0.60). Invuity posted earnings per share of ($0.56) in the same quarter last year, which indicates a positive year-over-year growth rate of 1.8%. The company is expected to issue its next earnings report after the market closes on Tuesday, November 7th.
On average, analysts expect that Invuity will report full year earnings of ($2.39) per share for the current fiscal year, with EPS estimates ranging from ($2.51) to ($2.29). For the next fiscal year, analysts forecast that the business will post earnings of ($1.76) per share, with EPS estimates ranging from ($2.01) to ($1.62). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that cover Invuity.
IVTY has been the subject of a number of research reports. Piper Jaffray Companies restated a “buy” rating and set a $10.00 target price on shares of Invuity in a research report on Wednesday, July 26th. Northland Securities restated a “buy” rating and set a $13.00 target price on shares of Invuity in a research report on Tuesday, September 26th. Zacks Investment Research upgraded shares of Invuity from a “sell” rating to a “hold” rating in a research report on Wednesday, October 4th. Finally, ValuEngine upgraded shares of Invuity from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $11.00.
Shares of Invuity (NASDAQ IVTY) opened at $8.90 on Friday. The company has a current ratio of 3.07, a quick ratio of 2.63 and a debt-to-equity ratio of 1.51. Invuity has a 1-year low of $4.50 and a 1-year high of $9.70.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. CAPROCK Group Inc. lifted its position in Invuity by 28.6% during the third quarter. CAPROCK Group Inc. now owns 45,000 shares of the medical instruments supplier’s stock valued at $401,000 after purchasing an additional 10,000 shares during the period. OxFORD Asset Management LLP acquired a new position in Invuity during the second quarter valued at $374,000. B. Riley Financial Inc. acquired a new position in shares of Invuity in the second quarter worth about $3,625,000. Royce & Associates LP raised its position in shares of Invuity by 141.9% in the second quarter. Royce & Associates LP now owns 98,939 shares of the medical instruments supplier’s stock worth $717,000 after acquiring an additional 58,033 shares during the period. Finally, FMR LLC raised its position in shares of Invuity by 0.5% in the first quarter. FMR LLC now owns 829,564 shares of the medical instruments supplier’s stock worth $6,595,000 after acquiring an additional 4,264 shares during the period. Institutional investors own 66.02% of the company’s stock.
Invuity, Inc, a medical technology company, develops various surgical devices to address various surgical procedures in the United States. The company integrates its intelligent photonics technology platform into its single-use and reusable advanced surgical devices to address various critical intracavity illumination and visualization challenges.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Invuity Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invuity Inc. and related companies with MarketBeat.com's FREE daily email newsletter.